Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Choreo LLC

Choreo LLC lessened its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 24.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,249 shares of the company’s stock after selling 394 shares during the period. Choreo LLC’s holdings in Medpace were worth $416,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. R Squared Ltd acquired a new stake in Medpace in the fourth quarter valued at about $30,000. Stone House Investment Management LLC purchased a new position in shares of Medpace during the 3rd quarter worth approximately $33,000. Ashton Thomas Securities LLC acquired a new stake in shares of Medpace in the 3rd quarter valued at approximately $37,000. Capital Performance Advisors LLP purchased a new stake in shares of Medpace in the third quarter valued at approximately $46,000. Finally, True Wealth Design LLC grew its holdings in Medpace by 16,800.0% during the third quarter. True Wealth Design LLC now owns 169 shares of the company’s stock worth $56,000 after acquiring an additional 168 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

Medpace stock opened at $336.47 on Thursday. Medpace Holdings, Inc. has a fifty-two week low of $302.01 and a fifty-two week high of $459.77. The company has a market capitalization of $10.46 billion, a price-to-earnings ratio of 29.46, a PEG ratio of 1.85 and a beta of 1.36. The stock has a fifty day moving average of $343.90 and a two-hundred day moving average of $348.96.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 50.87% and a net margin of 17.66%. On average, analysts forecast that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on MEDP shares. TD Cowen reduced their target price on Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Robert W. Baird boosted their price objective on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. Baird R W cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Finally, William Blair reissued an “outperform” rating on shares of Medpace in a research note on Tuesday, October 22nd. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $381.44.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.